Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714

R. Haddad; M. Gillison; R. L. Ferris; K. Harrington; M. Monga; C. Baudelet; W. J. Geese; A. Argiris

doi:10.1093/annonc/mdw376.69

Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714

R. Haddad, M. Gillison, R. L. Ferris, K. Harrington, M. Monga, C. Baudelet, W. J. Geese, A. Argiris

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	vi350
Journal	Annals of Oncology
Volume	27
DOIs	https://doi.org/10.1093/annonc/mdw376.69
State	Published - Oct 1 2016
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdw376.69

Cite this

Haddad, R., Gillison, M., Ferris, R. L., Harrington, K., Monga, M., Baudelet, C., Geese, W. J., & Argiris, A. (2016). Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714. Annals of Oncology, 27, vi350. https://doi.org/10.1093/annonc/mdw376.69

Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714. / Haddad, R.; Gillison, M.; Ferris, R. L.; Harrington, K.; Monga, M.; Baudelet, C.; Geese, W. J.; Argiris, A.

In: Annals of Oncology, Vol. 27, 01.10.2016, p. vi350.

Research output: Contribution to journal › Article › peer-review

Haddad, R, Gillison, M, Ferris, RL, Harrington, K, Monga, M, Baudelet, C, Geese, WJ & Argiris, A 2016, 'Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714', Annals of Oncology, vol. 27, pp. vi350. https://doi.org/10.1093/annonc/mdw376.69

Haddad R, Gillison M, Ferris RL, Harrington K, Monga M, Baudelet C et al. Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714. Annals of Oncology. 2016 Oct 1;27:vi350. https://doi.org/10.1093/annonc/mdw376.69

Haddad, R. ; Gillison, M. ; Ferris, R. L. ; Harrington, K. ; Monga, M. ; Baudelet, C. ; Geese, W. J. ; Argiris, A. / Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714. In: Annals of Oncology. 2016 ; Vol. 27. pp. vi350.

@article{3e51178494694709908b71dbdd36155e,

title = "Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714",

author = "R. Haddad and M. Gillison and Ferris, {R. L.} and K. Harrington and M. Monga and C. Baudelet and Geese, {W. J.} and A. Argiris",

year = "2016",

month = oct,

day = "1",

doi = "10.1093/annonc/mdw376.69",

language = "English (US)",

volume = "27",

pages = "vi350",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714

AU - Haddad, R.

AU - Gillison, M.

AU - Ferris, R. L.

AU - Harrington, K.

AU - Monga, M.

AU - Baudelet, C.

AU - Geese, W. J.

AU - Argiris, A.

PY - 2016/10/1

Y1 - 2016/10/1

UR - http://www.scopus.com/inward/record.url?scp=85056443176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056443176&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdw376.69

DO - 10.1093/annonc/mdw376.69

M3 - Article

VL - 27

SP - vi350

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -

Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this